:: CLDF ::

Home | Contact Us | Bookmark

MASH

HCC

ALCOHOL LIVER DISEASE

PEDIATRIC LIVER DISEASE

Embassy of Education

Webcasts Abstract Library

Complications of Cirrhosis |Abstract Library

The summaries are free for public use. The Chronic Liver Disease Foundation will continue to add and archive summaries of articles deemed relevant to CLDF by the Board of Trustees and its Advisors.

Abstract Details


	First Drug for Treating Hepatorenal Syndrome

Am J Nurs. 2023 Feb 1;123(2):27. doi: 10.1097/01.NAJ.0000919728.07518.8e.

Diane S Aschenbrenner¹

Author information

¹Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch: diane.aschenbrenner@gmail.com.

Abstract

Terlipressin (Terlivaz) has been approved as the first drug to treat hepatorenal syndrome.The drug may cause serious or fatal respiratory failure. Nurses should confirm that patients have an oxygen saturation level by pulse oximetry of at least 90% in order to start therapy.

HEPATITIS

HBV
HCV
HDV

CLD HEALTH OUTCOMES

CIRRHOSIS

Cirrhosis
HE
HRS
Thrombocytopenia

MASH

Slide Library
Publications
Webcasts
Abstract Library Committee Members

CHOLESTATIC

PBC

HCC

Slide Library
Publications
Webcasts
Algorithm
Abstract Library Committee Members

ALCOHOL LIVER DISEASE

Recorded Educational Webinar

PEDIATRIC LIVER DISEASE

Webcasts
Slide Library
Abstract Library

About CLDF

Board of Trustees
Board of Advisors/Faculty
CLDF Committees
2024 GI Fellow Board of Advisors

Other Resources

Journal Abstracts

The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2024 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.

Subscribe